Andrew Callos, EVP, Chief Commercial Officer at CYTOKINETICS INC (CYTK), sold 104,972 shares at $65.95 ($6.9M) on 2025-12-05, disclosed to the SEC on 2025-12-05.
Scheduled sale ($6.9M) by EVP, Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.95 | 52,486 | $3.5M | 50.0% |
| 2 | $65.95 | 52,486 | $3.5M | 50.0% |
| Total | $65.95 avg | 104,972 | $6.9M | 100% |
| Filing → |
| CYTK | SELL | 2026-07-02 | $1.3M | — | Filing → |
| CYTK | SELL | 2026-06-01 | $1.1M | — | Filing → |
| CYTK | SELL | 2026-05-05 | $875K | — | Filing → |